1. Home
  2. SMWB vs HELP Comparison

SMWB vs HELP Comparison

Compare SMWB & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Similarweb Ltd.

SMWB

Similarweb Ltd.

HOLD

Current Price

$2.66

Market Cap

240.7M

Sector

Technology

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$5.10

Market Cap

249.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SMWB
HELP
Founded
2007
N/A
Country
Israel
Canada
Employees
N/A
50
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
240.7M
249.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SMWB
HELP
Price
$2.66
$5.10
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$8.13
$95.00
AVG Volume (30 Days)
388.5K
1.2M
Earning Date
05-12-2026
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.11
N/A
Revenue Next Year
$11.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$4.29
52 Week High
$10.75
$8.55

Technical Indicators

Market Signals
Indicator
SMWB
HELP
Relative Strength Index (RSI) 40.32 46.84
Support Level $2.51 $4.41
Resistance Level $2.93 $7.28
Average True Range (ATR) 0.16 0.32
MACD 0.07 0.09
Stochastic Oscillator 52.22 85.57

Price Performance

Historical Comparison
SMWB
HELP

About SMWB Similarweb Ltd.

Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: